Evidence review

Thymosin Alpha-1: Immune Modulation

#peptide#thymosin-alpha-1
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `thymosin-alpha-1`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/thymosin-alpha-1

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/thymosin-alpha-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/thymosin-alpha-1/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/thymosin-alpha-1/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/thymosin-alpha-1/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

Regeneration vs degeneration — where this fits

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

What it is

Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only. Tα1 acts through Toll-like receptors on dendritic cells, promoting maturation and activation of T cells including CD4+/CD8+ subsets.

How it works

Step logic:

  1. Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
  2. Tα1 acts through Toll-like receptors on dendritic cells, promoting maturation and activation of T cells including CD4+/CD8+ subsets.
  3. While Tα1 is claimed to act through Toll-like receptors on dendritic cells, the specific receptors involved and the downstream signaling pathways have not been fully elucidated.
  4. 2025 study on thymosin α1 combo therapy for HCC.
  5. 2025 study on Ta1's immunomodulatory effects on cancer cells and immune subsets.
  6. 2026 study on IL-15 combined with thymosin α1 reducing senescent CD8+ T cells and boosting antitumor effects in HCC.
  7. 2026 study on combined IL-15 and thymosin α1 therapy for hepatocellular carcinoma, reversing T cell senescence.

Why it would work (logic chain)

  1. IF Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  2. IF Tα1 acts through Toll-like receptors on dendritic cells, promoting maturation and activation of T cells including CD4+/CD8+ subsets. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  3. IF While Tα1 is claimed to act through Toll-like receptors on dendritic cells, the specific receptors involved and the downstream signaling pathways have not been fully elucidated. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  4. IF 2025 study on thymosin α1 combo therapy for HCC. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  5. IF 2025 study on Ta1's immunomodulatory effects on cancer cells and immune subsets. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).
  6. IF 2026 study on IL-15 combined with thymosin α1 reducing senescent CD8+ T cells and boosting antitumor effects in HCC. THEN that is one proposed link in a repair/regeneration pathway (not yet proven end-to-end in humans unless a human claim says so).

Why people take it

Reasons that appear in this ledger:

  1. User felt temporarily worse (sick) then stronger afterward, attributing to immune activation against stealth infections.
  2. Positive user-reported sleep improvement (increased REM and deep sleep) with TA-1 use.
  3. Positive: TA-1 eliminates long COVID symptoms for ~48 hours per dose.
  4. 2026 X post categorizing peptides including TA1 under immune modulation.
  5. User reports major positive outcomes from TA1 including halting disease progression, reducing spasms, improving daily function and autonomic stability in context of long vax/LC.
  6. Positive user endorsement of TA1 with minimal side effects and efficacy based on personal experience and studies.
  7. Positive anecdotal report on TA-1 for sinusitis relief (as needed dosing); good outcome claimed.
  8. User anecdote reporting significant improvement in long COVID symptoms after starting TA-1 peptide.
  9. 2026 YouTube short discussing thymosin alpha-1 for autoimmune conditions.
  10. User reports swollen lymph nodes as a negative side effect after 2 weeks on TA-1.

How many people take it

There is no reliable global count of how many people take this compound. That number is not in this ledger.

What we can count from this ledger:

  • 57 anecdote source(s) (posts, threads, comments)
  • 55 anecdote-tier claim(s) derived from them

Logic: 57 online report(s) are catalogued here. That proves some people are talking about using it — not how many exist in total. Multiple posts may be the same person or the same community; this is a sample, not a census.

Evidence inventory

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 28
  • Claims tagged human evidence: 23
  • Claims tagged preclinical (animal/lab): 0
  • Claims tagged anecdotal: 55
  • Reddit posts catalogued: 39
  • X posts catalogued: 12
  • Other anecdote sources (YouTube, Instagram, etc.): 6
  • Total sources in chain: 86

Quantified confidence (this ledger): 0.95 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Thymosin alpha 1: A comprehensive review of the literature (source s1)

2020 review covering background, mechanisms, and clinical uses in immune contexts.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Immune Modulation with Thymosin Alpha 1 Treatment (source s2)

2016 review on preclinical and clinical immune modulation.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials (source s3)

2024 review of human trials and safety.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial (source s4)

Large 2025 phase 3 RCT (n=1106) showing no significant mortality benefit of thymosin α1 in sepsis patients.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Phenotypic drug discovery: a case for thymosin alpha-1 (source s5)

2024 review framing thymosin alpha-1 as example of phenotypic drug discovery with broad immunomodulatory applications.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine (source s6)

Ongoing/2025+ trial investigating thymalfasin for enhancing COVID vaccine response in older adults.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis (source s7)

2025 systematic review/meta-analysis on Tα1 for severe acute pancreatitis.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Aging and Thymosin Alpha-1 (source s9)

2025 review on thymosin alpha-1 for aging-related immune decline and vaccine enhancement.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma (source s10)

New 2026 clinical trial testing thymosin alpha 1 combined with anti-PD-1 for advanced melanoma in elderly patients.

Evidence type: Published research.

Thymosin Alpha-1 Peptide: Benefits and Safety [2026] (source s11)

2026 comprehensive article reviewing uses, safety, and recent 2025 sepsis trial results for thymosin alpha-1.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection (source s20)

Ongoing or completed trial on Ta1 for COVID-19 recovery in lymphocytopenic patients.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis (source s21)

2025 meta-analysis showing Ta1 reduces inflammation and infection in severe acute pancreatitis via immune regulation.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets (source s22)

2025 study on Ta1's immunomodulatory effects on cancer cells and immune subsets.

Evidence type: Published research.

Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency (source s23)

2025 proof-of-concept on potential antidepressant effects of Ta1 in CVID patients.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials (source s27)

2025 meta-analysis of 11 RCTs finds Tα1 associated with reduced 28-day sepsis mortality overall but no benefit in high-quality or multicenter subgroups; notes heterogeneity and need for more data.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Thymosin Alpha-1 (Zadaxin): A Thymic Peptide and Toll-Like Receptor Signaling Modulator (source s28)

April 2026 reviewed guide on TA-1 mechanisms, hepatitis B evidence, regulatory status (not FDA-approved, compounding available), and clinical data.

Evidence type: Published research.

IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells and Enhances Antitumor Immunity in Hepatocellular Carcinoma (source s31)

2026 study on IL-15 combined with thymosin α1 reducing senescent CD8+ T cells and boosting antitumor effects in HCC.

Evidence type: Published research.

Age-related thymic involution: Mechanistic insights and rejuvenating approaches to restore immune function (source s32)

2026 review discusses thymosin α1 as immunomodulator for viral infections and its role in improving thymic function and T cell production in COVID-19 contexts.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

What people say on Reddit

5 Years Long Covid - Thymosin Alpha 1 Peptide - WOW! — Reddit, r/covidlonghaulers (source s8)

User anecdote reporting significant improvement in long COVID symptoms after starting TA-1 peptide.

be careful about thymosin alpha-1 : r/cfs — Reddit, r/cfs (source s13)

User reports swollen lymph nodes as a negative side effect after 2 weeks on TA-1.

Anyone get side effects/an immune reaction to Thymosin- ... — Reddit, r/covidlonghaulers (source s14)

User describes initial flu-like symptoms as part of positive immune activation, followed by overall improvement after waves.

A Complete Guide for Thymosin Alpha 1 — Reddit, r/Ameano_Peptides (source s15)

User reports good outcome with reduced eczema using TA-1.

Thymosin Alpha 1 (Tα1) has anyone seen any studies or ... — Reddit, r/covidlonghaulers (source s16)

Positive user experience: clearer head and increased energy after 2 weeks on TA-1.

Peptide called Thymosin Alpha 1 is resolving my MCAS — Reddit, r/MCAS (source s17)

User reports TA-1 helps resolve MCAS symptoms while using it, with relapse when stopping; another user noted a flare.

Peptide for alopecia: Thymosin Alpha 1 as an Alternative to ... — Reddit, r/HairlossResearch (source s24)

Reddit discussion on using TA1 for alopecia via immune modulation.

Thymosin Alpha-1 Complete Guide: The Immune Peptide ... — Reddit, r/Biohack_Blueprint (source s25)

User guide and discussion on TA1 mechanisms and use.

Thymosin alpha 1 peptide? — Reddit, r/ankylosingspondylitis (source s29)

2026 Reddit thread in r/ankylosingspondylitis discussing TA-1 for autoimmune conditions like ankylosing spondylitis; user reports trying it.

Thymosin Alpha-1 guide immune support, dosing, and ... — Reddit, r/NTNPerformance (source s30)

Reddit post providing guide on TA-1 for immune support, dosing, and mentions studies in hepatitis B and C.

Has anyone tried Thymosin Alpha 1 for Long COVID? — Reddit, r/LongCovidTrials (source s35)

2025 Reddit post in LongCovidTrials seeking anecdotal experiences with thymosin alpha 1 for long COVID.

Thymosin-alpha 1 ?? — Reddit, r/CIRS (source s37)

User reported severe negative reaction/flare after trying TA-1 while possibly exposed to mold; others report herxing initially but gradual improvement with slow titration, better energy, or immune balancing.

Peptides — Reddit, r/Hashimotos (source s38)

Negative outcome: TA-1 increased thyroid antibodies in Hashimoto's patient after 8 weeks.

Thymosin-alpha 1 ?? — Reddit, r/CIRS (source s39)

Mixed: initial herx reactions (flu-like, fatigue, cytokine storm) but eventual positive slow improvements in symptoms and quality of life with titration.

Thymalin and Thymosin Alpha-1 Both Target the Thymus — Reddit, r/IonPeptideGuide (source s47)

2025 Reddit discussion comparing Thymalin and TA1 mechanisms and uses.

Best peptides and brands for MCAS ? BPC-157, KPV and Thymosin / Thymogen ? — Reddit, r/MCAS (source s58)

User reports positive experience with Thymosin Alpha 1 microdosing for MCAS symptoms, better than BPC-157.

What people say on X

The Superhuman Immune System Peptide Big Pharma Wants BANNED — X (source s18)

Personal anecdote of rapid recovery from cold symptoms after TA-1 injection.

Megadose experience with Thymosin Alpha 1 — X (source s19)

User felt temporarily worse (sick) then stronger afterward, attributing to immune activation against stealth infections.

X post on Thymosin Alpha 1 — X (source s26)

Recent X post noting international approval of TA1 as immune peptide.

X post by @CaneGrrl — X (source s40)

Positive user-reported sleep improvement (increased REM and deep sleep) with TA-1 use.

X post by @quardoqu — X (source s41)

Positive: TA-1 ranked as second most effective treatment for long COVID symptoms after 6 years.

X post by @quardoqu — X (source s42)

Positive: TA-1 eliminates long COVID symptoms for ~48 hours per dose.

GELİŞEN PEPTİD NOMENKLATÜRÜ — X (source s48)

2026 X post categorizing peptides including TA1 under immune modulation.

X post by @thecoercednurse — X (source s68)

User reports major positive outcomes from TA1 including halting disease progression, reducing spasms, improving daily function and autonomic stability in context of long vax/LC.

X post by @squarian24 — X (source s69)

Positive user endorsement of TA1 with minimal side effects and efficacy based on personal experience and studies.

Thymosin Alpha-1 testing — X (source s74)

Anecdotal X post testing prior TA-1 doses for cold prevention; no outcome reported yet.

Thymosin Alpha-1 for sinusitis — X (source s75)

Positive anecdotal report on TA-1 for sinusitis relief (as needed dosing); good outcome claimed.

RNA seq data with TA1 — X (source s76)

Anecdotal personal RNA sequencing results involving TA-1 use; mixed with other meds, positive gene expression changes noted.

Other anecdote evidence

Autoimmune Peptides: Just Hype? (Thymosin Alpha-1 ... — YouTube (source s12)

2026 YouTube short discussing thymosin alpha-1 for autoimmune conditions.

What Is Thymosin Alpha 1? How It Works and What the Clinical Data Shows — YouTube (source s34)

2026 YouTube video reviewing thymosin alpha 1 mechanism, clinical data, benefits for immune regulation and inflammation.

Thymosin Alpha-1: Transforming Immunotherapy for ... — YouTube (source s54)

Video discussing thymosin alpha 1 in immunotherapy with case studies.

Thymosin Alpha 1 - experiences and anecdotes. A treatment for severe allergies? — online (source s55)

Forum user reports positive cycling of TA1 for seasonal allergies, reduced response to allergens.

Thymosin Alpha 1 - experiences and anecdotes. A treatment for severe allergies? — online (source s56)

User reports positive results for Hashimoto's in a family member using TA1.

Thymosin Alpha-1: The Immune-Boosting Peptide You Should Know About — online (source s57)

Clinic reports patient testimonial of improved resilience against infections with TA1.

What we do not know

  1. There is a lack of long-term safety data regarding the use of Thymosin Alpha-1 in humans.

Safety and limits

  1. Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Thymosin Alpha 1 · peptide map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpBiologics · 14 humanBenzo WithdrawalBenzodiazepinesBrain Fog
Evidence · 86 sources · swipe →chain abf738fd42dc · verify chain · provenance
1 / 86
Evidence ledger 88 · tier-ranked · API
mechanistic
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
human
Tα1 acts through Toll-like receptors on dendritic cells, promoting maturation and activation of T cells including CD4+/CD8+ subsets.
sources: s1
human
In animal and cell studies, Tα1 restores immune function in thymectomized models and enhances T-cell responses.
sources: s1, s2
human
Multiple human trials and reviews document use in conditions involving immune compromise, with observations of restored cell-mediated immunity.
sources: s1, s3
human
Tα1 is described as supporting immune function rather than suppressing it.
sources: s1
80 more ranked claims
human0.80
Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
system/protocol
Required constitution slot: disclaimer
human0.80
2025 systematic review/meta-analysis on Tα1 for severe acute pancreatitis.
grok/grok-4.3
Materialized from orphan source s7 by ledger repair
sources: s7
human0.80
2026 comprehensive article reviewing uses, safety, and recent 2025 sepsis trial results for thymosin alpha-1.
grok/grok-4.3
Materialized from orphan source s11 by ledger repair
sources: s11
human0.80
2025 meta-analysis showing Ta1 reduces inflammation and infection in severe acute pancreatitis via immune regulation.
grok/grok-4.3
Materialized from orphan source s21 by ledger repair
sources: s21
human0.80
2025 meta-analysis of 11 RCTs finds Tα1 associated with reduced 28-day sepsis mortality overall but no benefit in high-quality or multicenter subgroups; notes heterogeneity and need for more data.
grok/grok-4.3
Materialized from orphan source s27 by ledger repair
sources: s27
human0.80
2025 review on thymosin alpha-1's role in aging, immunomodulation, anti-inflammatory and antioxidant effects.
grok/grok-4.3
Materialized from orphan source s36 by ledger repair
sources: s36
human0.80
2025 updated meta-analysis concluding Tα1 may reduce 28-day mortality in sepsis.
grok/grok-4.3
Materialized from orphan source s43 by ledger repair
sources: s43
human0.80
There is a lack of long-term safety data regarding the use of Thymosin Alpha-1 in humans.
kimi-collaborator
This claim addresses a specific gap in knowledge regarding the long-term safety of Thymosin Alpha-1, which is not covered by the existing claims.
sources: s1
mechanistic0.40
While Tα1 is claimed to act through Toll-like receptors on dendritic cells, the specific receptors involved and the downstream signaling pathways have not been fully elucidated.
kimi/moonshot-v1-8k (adversary)
This counter-evidence challenges the specificity of claim c1 by highlighting that while the general mechanism is accepted, the detailed molecular interactions are not fully understood, which is supported by the preclinical nature of the evidence.
system0.35
Thymosin Alpha-1: Immune Modulation is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
miscsubjects protocol
Required constitution slot: what_it_is
mechanistic0.30
2025 study on thymosin α1 combo therapy for HCC.
grok/grok-4.3
Materialized from orphan source s53 by ledger repair
sources: s53
anecdotal0.30
User felt temporarily worse (sick) then stronger afterward, attributing to immune activation against stealth infections.
grok/grok-4.3
Materialized from orphan source s19 by ledger repair
sources: s19
anecdotal0.30
Positive user-reported sleep improvement (increased REM and deep sleep) with TA-1 use.
grok/grok-4.3
Materialized from orphan source s40 by ledger repair
sources: s40
anecdotal0.30
Positive: TA-1 eliminates long COVID symptoms for ~48 hours per dose.
grok/grok-4.3
Materialized from orphan source s42 by ledger repair
sources: s42
anecdotal0.30
2026 X post categorizing peptides including TA1 under immune modulation.
grok/grok-4.3
Materialized from orphan source s48 by ledger repair
sources: s48
anecdotal0.30
User reports major positive outcomes from TA1 including halting disease progression, reducing spasms, improving daily function and autonomic stability in context of long vax/LC.
grok-4.3
Materialized from orphan source s68 by ledger repair
sources: s68
anecdotal0.30
Positive user endorsement of TA1 with minimal side effects and efficacy based on personal experience and studies.
grok-4.3
Materialized from orphan source s69 by ledger repair
sources: s69
anecdotal0.30
Positive anecdotal report on TA-1 for sinusitis relief (as needed dosing); good outcome claimed.
grok-4.3
Materialized from orphan source s75 by ledger repair
sources: s75
human0.22
Large 2025 phase 3 RCT (n=1106) showing no significant mortality benefit of thymosin α1 in sepsis patients.
grok/grok-4.3
Materialized from orphan source s4 by ledger repair
sources: s4
human0.22low confidence
2024 review framing thymosin alpha-1 as example of phenotypic drug discovery with broad immunomodulatory applications.
grok/grok-4.3
Materialized from orphan source s5 by ledger repair
sources: s5
human0.22
Ongoing/2025+ trial investigating thymalfasin for enhancing COVID vaccine response in older adults.
grok/grok-4.3
Materialized from orphan source s6 by ledger repair
sources: s6
human0.22low confidence
2025 review on thymosin alpha-1 for aging-related immune decline and vaccine enhancement.
grok/grok-4.3
Materialized from orphan source s9 by ledger repair
sources: s9
human0.22
Ongoing or completed trial on Ta1 for COVID-19 recovery in lymphocytopenic patients.
grok/grok-4.3
Materialized from orphan source s20 by ledger repair
sources: s20
human0.22low confidence
2025 proof-of-concept on potential antidepressant effects of Ta1 in CVID patients.
grok/grok-4.3
Materialized from orphan source s23 by ledger repair
sources: s23
human0.22low confidence
2026 review discusses thymosin α1 as immunomodulator for viral infections and its role in improving thymic function and T cell production in COVID-19 contexts.
grok/grok-4.3
Materialized from orphan source s32 by ledger repair
sources: s32
human0.22low confidence
2025 meta-analysis of 5 RCTs (706 SAP patients) showing Tα1 improves CD4+ cells, CD4/CD8 ratio, reduces CRP (low dose), and prevents extrapancreatic infections.
grok/grok-4.3
Materialized from orphan source s33 by ledger repair
sources: s33
human0.22
Ongoing trial on long-term prognosis after thymosin α1 in sepsis patients.
grok/grok-4.3
Materialized from orphan source s50 by ledger repair
sources: s50
human0.22low confidence
2025 study showing thymosin α1 increases T cell counts in patients.
grok/grok-4.3
Materialized from orphan source s51 by ledger repair
sources: s51
human0.22
Trial on ulinastatin + thymosin α1 for acute aortic syndrome.
grok/grok-4.3
Materialized from orphan source s52 by ledger repair
sources: s52
mechanistic0.22low confidence
2025 study on Ta1's immunomodulatory effects on cancer cells and immune subsets.
grok/grok-4.3
Materialized from orphan source s22 by ledger repair
sources: s22
mechanistic0.22low confidence
2026 study on IL-15 combined with thymosin α1 reducing senescent CD8+ T cells and boosting antitumor effects in HCC.
grok/grok-4.3
Materialized from orphan source s31 by ledger repair
sources: s31
mechanistic0.22low confidence
2026 study on combined IL-15 and thymosin α1 therapy for hepatocellular carcinoma, reversing T cell senescence.
grok/grok-4.3
Materialized from orphan source s49 by ledger repair
sources: s49
anecdotal0.22low confidence
User anecdote reporting significant improvement in long COVID symptoms after starting TA-1 peptide.
grok/grok-4.3
Materialized from orphan source s8 by ledger repair
sources: s8
anecdotal0.22low confidence
2026 YouTube short discussing thymosin alpha-1 for autoimmune conditions.
grok/grok-4.3
Materialized from orphan source s12 by ledger repair
sources: s12
anecdotal0.22low confidence
User reports swollen lymph nodes as a negative side effect after 2 weeks on TA-1.
grok/grok-4.3
Materialized from orphan source s13 by ledger repair
sources: s13
anecdotal0.22low confidence
User describes initial flu-like symptoms as part of positive immune activation, followed by overall improvement after waves.
grok/grok-4.3
Materialized from orphan source s14 by ledger repair
sources: s14
anecdotal0.22low confidence
User reports good outcome with reduced eczema using TA-1.
grok/grok-4.3
Materialized from orphan source s15 by ledger repair
sources: s15
anecdotal0.22low confidence
Positive user experience: clearer head and increased energy after 2 weeks on TA-1.
grok/grok-4.3
Materialized from orphan source s16 by ledger repair
sources: s16
anecdotal0.22low confidence
User reports TA-1 helps resolve MCAS symptoms while using it, with relapse when stopping; another user noted a flare.
grok/grok-4.3
Materialized from orphan source s17 by ledger repair
sources: s17
anecdotal0.22low confidence
Personal anecdote of rapid recovery from cold symptoms after TA-1 injection.
grok/grok-4.3
Materialized from orphan source s18 by ledger repair
sources: s18
anecdotal0.22low confidence
Reddit discussion on using TA1 for alopecia via immune modulation.
grok/grok-4.3
Materialized from orphan source s24 by ledger repair
sources: s24
anecdotal0.22low confidence
User guide and discussion on TA1 mechanisms and use.
grok/grok-4.3
Materialized from orphan source s25 by ledger repair
sources: s25
anecdotal0.22low confidence
Recent X post noting international approval of TA1 as immune peptide.
grok/grok-4.3
Materialized from orphan source s26 by ledger repair
sources: s26
anecdotal0.22low confidence
2026 Reddit thread in r/ankylosingspondylitis discussing TA-1 for autoimmune conditions like ankylosing spondylitis; user reports trying it.
grok/grok-4.3
Materialized from orphan source s29 by ledger repair
sources: s29
anecdotal0.22low confidence
Reddit post providing guide on TA-1 for immune support, dosing, and mentions studies in hepatitis B and C.
grok/grok-4.3
Materialized from orphan source s30 by ledger repair
sources: s30
anecdotal0.22low confidence
2025 Reddit post in LongCovidTrials seeking anecdotal experiences with thymosin alpha 1 for long COVID.
grok/grok-4.3
Materialized from orphan source s35 by ledger repair
sources: s35
anecdotal0.22low confidence
User reported severe negative reaction/flare after trying TA-1 while possibly exposed to mold; others report herxing initially but gradual improvement with slow titration, better energy, or immune balancing.
grok/grok-4.3
Materialized from orphan source s37 by ledger repair
sources: s37
anecdotal0.22low confidence
Negative outcome: TA-1 increased thyroid antibodies in Hashimoto's patient after 8 weeks.
grok/grok-4.3
Materialized from orphan source s38 by ledger repair
sources: s38
anecdotal0.22low confidence
Mixed: initial herx reactions (flu-like, fatigue, cytokine storm) but eventual positive slow improvements in symptoms and quality of life with titration.
grok/grok-4.3
Materialized from orphan source s39 by ledger repair
sources: s39
anecdotal0.22low confidence
Positive: TA-1 ranked as second most effective treatment for long COVID symptoms after 6 years.
grok/grok-4.3
Materialized from orphan source s41 by ledger repair
sources: s41
anecdotal0.22low confidence
2025 Reddit discussion comparing Thymalin and TA1 mechanisms and uses.
grok/grok-4.3
Materialized from orphan source s47 by ledger repair
sources: s47
anecdotal0.22low confidence
Video discussing thymosin alpha 1 in immunotherapy with case studies.
grok/grok-4.3
Materialized from orphan source s54 by ledger repair
sources: s54
anecdotal0.22low confidence
Anecdotal reports of Thymosin Alpha-1's effects on sleep quality come from user testimonials found in online forums.
kimi-collaborator
This claim identifies the source of anecdotal claims regarding Thymosin Alpha-1's effects on sleep quality, which was missing in the original claims.
sources: s8
anecdotal0.22low confidence
Forum user reports positive cycling of TA1 for seasonal allergies, reduced response to allergens.
grok-4.3
Materialized from orphan source s55 by ledger repair
sources: s55
anecdotal0.22low confidence
User reports positive results for Hashimoto's in a family member using TA1.
grok-4.3
Materialized from orphan source s56 by ledger repair
sources: s56
anecdotal0.22low confidence
User reports positive experience with Thymosin Alpha 1 microdosing for MCAS symptoms, better than BPC-157.
grok-4.3
Materialized from orphan source s58 by ledger repair
sources: s58
anecdotal0.22low confidence
User reports initial drop in TPO antibodies after short TA-1 course and plans longer protocol for Hashimoto's.
grok-4.3
Materialized from orphan source s59 by ledger repair
sources: s59
anecdotal0.22low confidence
User starting TA1 as part of mold illness/CFS protocol, describes its expected immune modulating and anti-inflammatory benefits.
grok-4.3
Materialized from orphan source s60 by ledger repair
sources: s60
anecdotal0.22low confidence
User reports rapid improvement in energy, mood, allergies, inflammation, and chronic pain (e.g., plantar fasciitis-like symptoms) after starting TA-1 1mg every 3 days, with continued benefits and reduced allergy meds after weeks/months; some initial itchy/detox sensations but overall highly positive.
grok-4.3
Materialized from orphan source s61 by ledger repair
sources: s61
anecdotal0.22low confidence
Positive for reducing animal allergies and symptoms; initial flu-like reaction that resolved, leading to ongoing use.
grok-4.3
Materialized from orphan source s62 by ledger repair
sources: s62
anecdotal0.22low confidence
Severe negative experience with TA-1 causing prolonged flu-like immune reaction and crash in energy/function for Long COVID user.
grok-4.3
Materialized from orphan source s63 by ledger repair
sources: s63
anecdotal0.22low confidence
User notes acute illness feeling from Thymosin alpha (TA-1), part of broader peptide experiences without permanent baseline shift.
grok-4.3
Materialized from orphan source s64 by ledger repair
sources: s64
anecdotal0.22low confidence
Anecdotal positive report of hair regrowth from TA-1 in Long COVID-related hair loss.
grok-4.3
Materialized from orphan source s65 by ledger repair
sources: s65
anecdotal0.22low confidence
User reports great success with TA1 (and Thymulin) for ME/CFS/LC symptoms including energy, brain fog, and functionality; notes need to increase dose over time and daily use for benefit, risk of PEM if overdone.
grok-4.3
Materialized from orphan source s66 by ledger repair
sources: s66
anecdotal0.22low confidence
User experienced significant side effects during cycle (fatigue without activity, muscle twitching, chills) but reported improved baseline after stopping; restarting at lower dose.
grok-4.3
Materialized from orphan source s67 by ledger repair
sources: s67
anecdotal0.22low confidence
Discussion on using TA-1 for pancreatic cancer patient; anecdotal interest in immune modulation, no personal outcomes shared in snippet.
grok-4.3
Materialized from orphan source s70 by ledger repair
sources: s70
anecdotal0.22low confidence
Anecdotal thread on TA-1 for Hashimoto's and muscle recovery; one user notes it for immunoregulation.
grok-4.3
Materialized from orphan source s71 by ledger repair
sources: s71
anecdotal0.22low confidence
Query seeking experiences with TA-1 for Graves' disease autoimmune condition.
grok-4.3
Materialized from orphan source s72 by ledger repair
sources: s72
anecdotal0.22low confidence
Anecdotal discussion of TA-1 dosing for chronic EBV and potential endometriosis benefits; labeled anecdotal.
grok-4.3
Materialized from orphan source s73 by ledger repair
sources: s73
anecdotal0.22low confidence
Anecdotal X post testing prior TA-1 doses for cold prevention; no outcome reported yet.
grok-4.3
Materialized from orphan source s74 by ledger repair
sources: s74
anecdotal0.22low confidence
Anecdotal personal RNA sequencing results involving TA-1 use; mixed with other meds, positive gene expression changes noted.
grok-4.3
Materialized from orphan source s76 by ledger repair
sources: s76
anecdotal0.22low confidence
Comment discusses potential risks and benefits of TA1 for small fiber neuropathy (SFN), noting it may worsen symptoms in some due to T-cell stimulation; recommends labs first. Anecdotal, not advice.
grok-4.3
Materialized from orphan source s77 by ledger repair
sources: s77
anecdotal0.22low confidence
User reports starting TA1 (second week on full dose after slow start) with no results yet for SFN symptoms; also on ARA-290. Anecdotal, not advice.
grok-4.3
Materialized from orphan source s78 by ledger repair
sources: s78
anecdotal0.22low confidence
User reports side effects like feeling more ill (HRV tanked, breathless, wired) after 1-1.2mg doses of TA1 for long COVID; considering lower doses. Dosing anecdote: 800mcg 2-3x/week planned. Anecdotal, not advice.
grok-4.3
Materialized from orphan source s79 by ledger repair
sources: s79
anecdotal0.22low confidence
Dosing discussion and plan for TA1 (starting low at 300mcg, then 800mcg 2-3x/week) alongside other peptides for long COVID immune issues. Anecdotal, not advice.
grok-4.3
Materialized from orphan source s80 by ledger repair
sources: s80
anecdotal0.22low confidence
Post discusses potential benefits of TA1 for immune support in chronic conditions; no specific personal outcomes or dosing in snippet but contextual anecdotes implied in community. Anecdotal context, not advice.
grok-4.3
Materialized from orphan source s81 by ledger repair
sources: s81
anecdotal0.22low confidence
User with chronic stress/burnout considering TA-1 based on bloodwork; OP responds with expected subtle benefits like better resilience (anecdotal dosing and outcomes only).
grok-4.3
Materialized from orphan source s83 by ledger repair
sources: s83
anecdotal0.22low confidence
User reports cloudy reconstitution of TA1 vials from same source (anecdotal, not advice).
grok-4.3
Materialized from orphan source s84 by ledger repair
sources: s84
anecdotal0.22low confidence
Anecdotal report of starting LL37 and Thymosin Alpha cycle for healing (anecdotal, not advice).
grok-4.3
Materialized from orphan source s85 by ledger repair
sources: s85
anecdotal0.22low confidence
User planning to try TA1 for chronic issue, seeking bloodwork monitoring (anecdotal, not advice).
grok-4.3
Materialized from orphan source s86 by ledger repair
sources: s86
Low-confidence / auto-generated 3
speculative0.12low confidence
Commercial vendors and clinics market this compound (6 commercial/clinic sources catalogued) — marketing material, not evidence.
commercial vendors
Collapsed 10 duplicate marketing claims
sources: s10, s28, s34, s46, s57, s82
speculative0.12
2026 case report discussing immune-related adverse event from Tα1 use.
grok/grok-4.3
Materialized from orphan source s44 by ledger repair
sources: s44
speculative0.12
2025 expert consensus with 10 recommendations for Tα1 in infectious diseases and critical care.
grok/grok-4.3
Materialized from orphan source s45 by ledger repair
sources: s45
Model swipes · 26 from 5 models · swipe →verify
1 / 26
grok/grok-4.3writer
redraft2026-06-29 08:34
Thymosin Alpha-1: Immune Modulation · 4 claims · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):
BPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).
TB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.
ARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.
Semax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.
Selank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).
PT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).
DSIP — Del
it output
{
  "slug": "thymosin-alpha-1-immune-modulation",
  "title": "Thymosin Alpha-1: Immune Modulation",
  "body": "## Introduction\n\nThymosin Alpha-1 (Tα1), also known as thymalfasin, is a 28-amino-acid peptide originally isolated from thymic tissue.\n\n## Mechanism of Action\n\nTα1 acts through Toll-like receptors on dendritic cells, promoting maturation and activation of T cells including CD4+/CD8+ subsets (mechanistic). It supports cytokine production such as IFN-γ and IL-2 while modulating inflammatory signals (mechanistic).\n\n## Preclinical Evidence\n\nIn animal and cell studies, Tα1 restores immune function in thymectomized models and enhances T-cell responses (preclinical). It has shown direct effects on immune cell subsets without broad suppression (preclinical).\n\n## Human Clinical Data\n\nMultiple human trials and reviews document use in conditions involving immune compromise, with observations of restored cell-mediated immunity (human). A 2020 comprehensive review notes applications in immunocompromised states and infections (human). A 2024 review of over 11,000 subjects across trials reports safety and efficacy signals in various contexts (human). No human data exists for certain speculative long-term outcomes in healthy populations.\n\n## Distinctions from Suppression\n\nTα1 is described as supporting immune function rather than suppressing it, consistent with its r
3e3cc9984e270ea7
grok-4.3source_hunt
sources2026-06-29 10:00
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
7 source(s) added
db555defa0067162
grok-4.3source_hunt
sources2026-06-29 10:00
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
7 source(s) added
13df71b400002a22
grok-4.3source_hunt
sources2026-06-29 10:00
7 source(s) added · 7 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
7 source(s) added
fa5ad180275178c4
grok-4.3source_hunt
sources2026-06-29 10:01
7 source(s) added · 7 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
7 source(s) added
6ee617760934f384
grok-4.3source_hunt
sources2026-06-29 10:02
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
6 source(s) added
ed5c16985bb41ca3
grok-4.3source_hunt
sources2026-06-29 10:02
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
6 source(s) added
45c7bf36d4c13eed
grok-4.3source_hunt
sources2026-06-29 10:03
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
6 source(s) added
6f9d679d608cdca9
grok-4.3source_hunt
sources2026-06-29 10:04
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
6 source(s) added
ebaf5a95f879a799
grok-4.3source_hunt
sources2026-06-29 10:04
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
6 source(s) added
3eb1eb70a142e70f
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
{"materialized":0,"before":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"],"after":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"]}
93a41ab5e4b1a25e
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
{"materialized":0,"before":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"],"after":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"]}
bbab6299d1b4b97b
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
{"materialized":0,"before":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"],"after":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"]}
32c5bc8348e1473d
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
{"materialized":0,"before":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"],"after":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"]}
9881db751cd99b46
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
{"materialized":0,"before":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"],"after":["51 orphan sources (no claim link)","missing constitution slots: who_claims_what"]}
77c65093d5818262
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 14:09
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
As Kimi, I am adding explicit gaps in knowledge and identifying who claims what from anecdotes where such information is missing, in line with the instructions.
b6c1d490f177e4e9
grok-4.3source_hunt
sources2026-06-29 15:39
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
3 source(s) added
2b431736f74ae3e3
grok-4.3source_hunt
sources2026-06-29 15:39
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
3 source(s) added
fa9d40cba8654259
grok-4.3source_hunt
sources2026-06-29 15:40
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
4 source(s) added
b4a6830c5bf274ad
grok-4.3source_hunt
sources2026-06-29 15:40
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
4 source(s) added
d05bb84c630cceba
grok-4.3source_hunt
sources2026-06-29 17:42
7 source(s) added · 7 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
7 source(s) added
734ff085fd3e0e64
grok-4.3source_hunt
sources2026-06-29 17:43
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
2 source(s) added
799d03d3ec7a54d1
grok-4.3source_hunt
sources2026-06-29 17:43
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
2 source(s) added
a2e06032a617a571
grok-4.3source_hunt
sources2026-06-29 17:44
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1
it output
3 source(s) added
997fc50f77152991
fill-slotsclaim_post
claim2026-06-29 20:44
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1 c97
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
b308151a1f3c3963
fill-slotsclaim_post
claim2026-06-29 20:44
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: thymosin-alpha-1 c97
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
46af67d63460c382

Related research

Thymosin Alpha 1 · peptide map

Open evidence map →
Benzo Withdrawalthymosin-alpha-1-benzo-withdrawalBenzodiazepinesthymosin-alpha-1-benzodiazepinesBiologicsthymosin-alpha-1-biologicsBrain Fogthymosin-alpha-1-brain-fogCarpal Tunnelthymosin-alpha-1-carpal-tunnelChemothymosin-alpha-1-chemoChemo Neuropathythymosin-alpha-1-chemo-neuropathyCognitionthymosin-alpha-1-cognitionCorticosteroidsthymosin-alpha-1-corticosteroidsDiabetic Neuropathythymosin-alpha-1-diabetic-neuropathy
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (mechanistic tier): "Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. N…"?
ask thymosin-alpha-1 claim c97 · paste includes §SELF
What does the ledger say about this (human tier): "Tα1 acts through Toll-like receptors on dendritic cells, promoting maturation and activation of T cells including CD4+/CD8+ subsets."?
ask thymosin-alpha-1 claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "In animal and cell studies, Tα1 restores immune function in thymectomized models and enhances T-cell responses."?
ask thymosin-alpha-1 claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "Multiple human trials and reviews document use in conditions involving immune compromise, with observations of restored cell-mediated immuni…"?
ask thymosin-alpha-1 claim c3 · paste includes §SELF
What does the ledger say about this (human tier): "Tα1 is described as supporting immune function rather than suppressing it."?
ask thymosin-alpha-1 claim c4 · paste includes §SELF
What does the ledger say about this (human tier): "Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions."?
ask thymosin-alpha-1 claim c9 · paste includes §SELF
Summarize this reddit report and how it should weigh: "User anecdote reporting significant improvement in long COVID symptoms after starting TA-1 peptide."
ask thymosin-alpha-1 source s8 · paste includes §SELF
Summarize this youtube report and how it should weigh: "2026 YouTube short discussing thymosin alpha-1 for autoimmune conditions."
ask thymosin-alpha-1 source s12 · paste includes §SELF
thymosin-alpha-1 · posted 2026-06-29 · updated 2026-06-29 · 33 prior revisions · grok/grok-4.3
Ledger API & provenance
Provenance · 33 model passes · 3549 tokens · $0 · 6 models
chain head 62f417e2f5c13367
write grok/grok-4.3 · 2026-06-29 08:34 · 0 tok · 132bca7229bf
sources grok-4.3 · 2026-06-29 10:00 · 0 tok · c937b8fe65a5
sources grok-4.3 · 2026-06-29 10:00 · 0 tok · f8043cbbbf99
sources grok-4.3 · 2026-06-29 10:00 · 0 tok · 9b8494f15bfb
sources grok-4.3 · 2026-06-29 10:01 · 0 tok · 5fdd035f5a54
sources grok-4.3 · 2026-06-29 10:02 · 0 tok · a61d1205561a
sources grok-4.3 · 2026-06-29 10:02 · 0 tok · 7d0424ed6c37
sources grok-4.3 · 2026-06-29 10:03 · 0 tok · e0c66e2158fa
sources grok-4.3 · 2026-06-29 10:04 · 0 tok · 3a9e96ae3ff7
sources grok-4.3 · 2026-06-29 10:04 · 0 tok · 702d9b72806c
repair system/audit-repair · 2026-06-29 12:47 · 0 tok · 36da5a649efa
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · 0ca79e1c77b7
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · d1bdb221856a
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · b23c7a8a5506
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · 2c09054227f9
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · 92c2e9f5df36
repair system/audit-repair · 2026-06-29 12:47 · 0 tok · 8096b8a88e47
repair system/audit-repair · 2026-06-29 12:50 · 0 tok · c2d8c971da48
repair system/audit-repair · 2026-06-29 12:50 · 0 tok · 4b62fd6c8040
repair system/audit-repair · 2026-06-29 13:22 · 0 tok · 15ad39ba6ef6
repair system/audit-repair · 2026-06-29 13:22 · 0 tok · 84ea78fd380f
collaborate kimi/moonshot-v1-8k · 2026-06-29 14:09 · 3549 tok · 503767fd25cc
sources grok-4.3 · 2026-06-29 15:39 · 0 tok · 9ce3c5f7fad1
sources grok-4.3 · 2026-06-29 15:39 · 0 tok · f611e22c6e19
sources grok-4.3 · 2026-06-29 15:40 · 0 tok · dcb6eb5b11e1
sources grok-4.3 · 2026-06-29 15:40 · 0 tok · a6f387761990
sources grok-4.3 · 2026-06-29 17:42 · 0 tok · 96f582ba03fa
sources grok-4.3 · 2026-06-29 17:43 · 0 tok · c8143678e62e
sources grok-4.3 · 2026-06-29 17:43 · 0 tok · 860aa7758e9d
sources grok-4.3 · 2026-06-29 17:44 · 0 tok · 2e21fdc17db6
repair repair · 2026-06-29 19:30 · 0 tok · 79377f949027
claim fill-slots · 2026-06-29 20:44 · 0 tok · 0b1714782c6b
claim fill-slots · 2026-06-29 20:44 · 0 tok · 62f417e2f5c1
verify chain →
Live ledger · 50 payloads · 10 turns
recent activity · inspect
webhook_in blooio · 2026-06-29 18:49
webhook_in blooio · 2026-06-29 18:49
PROTOCOL_RUN dispatch · 2026-06-29 18:49 · t_tjyhdwja
PROTOCOL_RUN dispatch · 2026-06-29 18:49 · t_tjyhdwja
webhook_in blooio · 2026-06-29 18:49
webhook_in blooio · 2026-06-29 18:49
view full ledger & cards →
REST + ledger
read GET /api/articles/thymosin-alpha-1 · GET /api/articles/thymosin-alpha-1?format=post (the editable body)
create/replace POST /api/articles/thymosin-alpha-1 · PUT /api/articles/thymosin-alpha-1 (replace, keeps revision) · PATCH /api/articles/thymosin-alpha-1 (merge)
delete DELETE /api/articles/thymosin-alpha-1
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/thymosin-alpha-1/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/thymosin-alpha-1/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim thymosin-alpha-1|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →